Teva Pharmaceuticals USA, a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd., is making a full-court press on getting the word out on the need for follow-on biologics. In its “Year of Affordable Healthcare [1]” campaign, Teva is putting put together videos to argue for generics, just as the White House is making its position known on the need for biogenerics [2] (read: need for lower costs).
The program commemorates the 25th anniversary of the Waxman-Hatch Act which created the modern generic drugs industry and features videos [1] that ask the “man on the street” in Washington, D.C. what they think about healthcare in the U.S. It wouldn’t take the Amazing Kreskin [3] to guess that people want lower healthcare costs. It’s a thorny issue with some biotech therapies costing as much as $500,000 annually.
See more here [4].